JP2022512948A5 - - Google Patents

Info

Publication number
JP2022512948A5
JP2022512948A5 JP2021524392A JP2021524392A JP2022512948A5 JP 2022512948 A5 JP2022512948 A5 JP 2022512948A5 JP 2021524392 A JP2021524392 A JP 2021524392A JP 2021524392 A JP2021524392 A JP 2021524392A JP 2022512948 A5 JP2022512948 A5 JP 2022512948A5
Authority
JP
Japan
Prior art keywords
cells
composition according
cell composition
isolated cell
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021524392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512948A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060477 external-priority patent/WO2020097466A1/en
Publication of JP2022512948A publication Critical patent/JP2022512948A/ja
Publication of JP2022512948A5 publication Critical patent/JP2022512948A5/ja
Pending legal-status Critical Current

Links

JP2021524392A 2018-11-08 2019-11-08 表現型特性が向上したｔ細胞組成物 Pending JP2022512948A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862757467P 2018-11-08 2018-11-08
US62/757,467 2018-11-08
US201962821031P 2019-03-20 2019-03-20
US62/821,031 2019-03-20
US201962867499P 2019-06-27 2019-06-27
US62/867,499 2019-06-27
PCT/US2019/060477 WO2020097466A1 (en) 2018-11-08 2019-11-08 T cell compositions with improved phenotypic properties

Publications (2)

Publication Number Publication Date
JP2022512948A JP2022512948A (ja) 2022-02-07
JP2022512948A5 true JP2022512948A5 (https=) 2022-11-14

Family

ID=70612526

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021524392A Pending JP2022512948A (ja) 2018-11-08 2019-11-08 表現型特性が向上したｔ細胞組成物

Country Status (12)

Country Link
US (2) US20200188435A1 (https=)
EP (1) EP3876979A4 (https=)
JP (1) JP2022512948A (https=)
KR (1) KR20210095157A (https=)
CN (2) CN113226359B (https=)
AU (1) AU2019375997A1 (https=)
BR (1) BR112021008963A2 (https=)
CA (1) CA3118757A1 (https=)
IL (1) IL282914A (https=)
MX (1) MX2021005372A (https=)
SG (1) SG11202104611YA (https=)
WO (1) WO2020097466A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
CN113880953A (zh) * 2020-07-01 2022-01-04 华夏英泰（北京）生物技术有限公司 T细胞抗原受体、其多聚体复合物及其制备方法和应用
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
JP7692633B2 (ja) * 2021-05-07 2025-06-16 康人 徳元 メモリーｔ細胞の製造方法
CN113388612A (zh) * 2021-06-18 2021-09-14 重庆天科雅生物科技有限公司 一种针对表位点为iyvlvmlvl的tcr所设计的引物及其应用
WO2024148216A2 (en) * 2023-01-05 2024-07-11 Neximmune, Inc. Combination therapy with t cell engager

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
JP3680219B2 (ja) * 1994-06-28 2005-08-10 独立行政法人理化学研究所 癌細胞障害性ｔリンパ球の誘導培養方法
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6140113A (en) 1996-03-28 2000-10-31 The Johns Hopkins University Polynucleotides encoding molecular complexes which modify immune responses
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US20050169898A1 (en) 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
DE60334474D1 (de) 2002-07-12 2010-11-18 Univ Johns Hopkins Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren
TW200502391A (en) 2003-05-08 2005-01-16 Xcyte Therapies Inc Generation and isolation of antigen-specific t cells
PT1956080E (pt) 2005-08-08 2011-12-30 San Raffaele Centro Fond Uso de il-7 e il-15 para a modificação genética de linfócitos t da memória
WO2009094273A2 (en) 2008-01-15 2009-07-30 Yale University Compositions and methods for adoptive and active immunotherapy
WO2010065544A2 (en) 2008-12-01 2010-06-10 The Johns Hopkins University Diagnostic and treatment methods for cancer based on immune inhibitors
WO2010099205A1 (en) 2009-02-24 2010-09-02 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (pml)
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
EP2404618A1 (en) 2010-07-07 2012-01-11 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Immunomodulatory protein constructs with a helical polymeric backbone.
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
US10758487B2 (en) 2011-12-09 2020-09-01 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
KR101749195B1 (ko) 2011-12-12 2017-06-20 셀 메디카 리미티드 T 세포들을 증식시키는 방법
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
US10463750B2 (en) 2013-02-15 2019-11-05 The Johns Hopkins University Antigen-Specific T cell redirectors
KR102164405B1 (ko) 2013-03-14 2020-10-12 더 존스 홉킨스 유니버시티 나노스케일 인공 항원 제시 세포
US11807675B2 (en) 2013-10-03 2023-11-07 The University Of Maryland, Baltimore Nanoparticle based artificial antigen presenting cell mediated activation of NKT cells
WO2015127190A1 (en) * 2014-02-21 2015-08-27 Argos Therapeutics, Inc. Tscm cells and methods for use
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
CN106062185A (zh) 2014-04-24 2016-10-26 美天旎生物技术有限公司 用于自动生成遗传修饰的t细胞的方法
HUE049514T2 (hu) 2014-04-25 2020-09-28 Bluebird Bio Inc Javított eljárások adoptív sejtterápiák kialakítására
RU2739770C2 (ru) * 2014-06-11 2020-12-28 полибайосепт ГмбХ Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
CA3017170C (en) 2014-09-17 2021-03-23 The Johns Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
AU2016341529B2 (en) 2015-10-22 2023-03-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
IL258935B2 (en) 2015-10-28 2024-08-01 Life Tech As Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio
BR112018008442A2 (pt) * 2015-11-05 2018-11-06 Juno Therapeutics Inc receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
EP3384012A1 (en) * 2015-12-04 2018-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of amplifying a population of antigen-specific memory cd4+ t cells using artificial presenting cells expressing hla class ii molecules
JP7016098B2 (ja) * 2016-03-16 2022-02-21 ネクシミューン インコーポレイテッド 抗原特異的ｔ細胞の生成
IT201700041430A1 (it) * 2017-04-13 2018-10-13 Sarong Spa Metodo e apparato per realizzare capsule con filtro
BR112020005552A2 (pt) * 2017-09-20 2020-10-27 Neximmune, Inc. composições de células compreendendo células t específicas de antígeno para terapia adotiva
EP3704229B1 (en) * 2017-11-01 2023-12-20 Juno Therapeutics, Inc. Process for producing a t cell composition

Similar Documents

Publication Publication Date Title
JP2022512948A5 (https=)
Couture et al. HLA-class II artificial antigen presenting cells in CD4+ T cell-based immunotherapy
US20240408200A1 (en) Methods of cell culture for adoptive cell therapy
JP7244461B2 (ja) 養子細胞療法のための改良型細胞培養方法
JP2020534313A5 (https=)
IL273452B1 (en) Cell preparations comprising antigen-specific T cells for adoptive therapy
US20250084145A1 (en) Method for establishing pluripotent stem cells bearing genes encoding antigen specific t cell receptor
Tsai et al. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells
US20180078627A1 (en) Method for antigen loading of dendritic cells and vaccine
Grupp et al. Adoptive cellular therapy
KR20210095157A (ko) 개선된 표현형 속성을 갖는 t 세포 조성물
Zhang et al. Generation of mouse pluripotent stem cell–derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells
van Eck van der Sluijs et al. Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses
WO2023082640A1 (zh) 增强免疫细胞持久性的方法
Rami et al. Induced pluripotent stem cell as a new source for cancer immunotherapy
Li et al. Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells
Shurin et al. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
JP2017131136A (ja) 血液由来単球の増殖誘導方法
JP2022513584A (ja) サイトカインを分泌するように改変されたｐｄｃ株
JP7337373B2 (ja) 抗原特異的ｔ細胞の製造方法
Koido et al. Antigen‐Specific Polyclonal Cytotoxic T Lymphocytes Induced by Fusions of Dendritic Cells and Tumor Cells
Narita et al. Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNA
EP4722349A1 (en) Pluripotent stem cell-derived cd4-positive t cells, method for production thereof, and use thereof
Sitkovskaya et al. The Effect of Oncolytic Reovirus P-92 on Dendritic Cell Maturation and Generation of Tumor-Specific Lymphocytes in vitro
RU2021116343A (ru) Композиции т-клеток с улучшенными фенотипическими свойствами